Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

Then in 2006, CAT was bought by AstraZeneca for £700 million, dashing hopes that the UK could produce a world-class biotech to rival the success of US companies Amgen and Genentech. This pattern ...

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

Combine this with a large increase in funding, and you could start to see the rewards of leading a UK biotech company to success start to become enticing – the $354 million that David Hung ...

PIC's gene-edited pigs are highly resistant to one of the most harmful viruses affecting pig populations worldwide today.

announced an investment and strategic partnership with UK-based Juvenescence , a longevity-focused biotechnology company. M42 was launched by G42 Healthcare , the healthcare arm of the UAE's ...

a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31 ...